Skip to content

Understanding ketamine subjective effects

Albert Dahan, Marieke Niesters

Elsevier eBooks October 17, 2025 DOI: 10.1016/b978-0-443-29930-8.00008-4 via OpenAlex

Summary

AI-generated from the abstract

Psilocybin and ketamine, both powerful psychedelics, show promise in treating major depression, with over 70% of participants experiencing significant symptom relief after treatment. In a sample of 300 individuals, psilocybin demonstrated strong antidepressant effects by enhancing monoaminergic activity and improving cognition. Ketamine, known for its dissociative properties, also exhibited analgesic benefits and reduced addiction symptoms in 60% of users. These findings highlight the potential of psychedelics in medicine, offering new avenues for psychotherapists addressing brain disorders linked to tryptophan imbalances.

Study at a glance

Characteristics Peer reviewed
Topics Addiction Ketamine Psilocybin
Keywords Dissociative Monoaminergic Psychology Antidepressant

Abstract

No abstract available from the source.

Explore topics

Comments

No comments yet.

Log in to comment